Overall Score

Political

No material political developments were reported this month.

The company remains exposed to general healthcare/consumer policy and reimbursement dynamics, but no new regulatory or government actions were cited.

Economic

The company continues to operate with negative profitability and weak cash generation, with TTM net profit margin at -15.7% and free cash flow yield at -0.3%.

Liquidity remains solid with a current ratio of 4.78, but valuation still reflects uncertainty at 2.52x sales and a negative EV/EBITDA multiple due to losses.

Social

No new consumer demand or brand sentiment developments were reported this month.

The business still benefits from a high gross margin profile of 73.7%, but operating performance remains pressured by elevated SG&A at 79.0% of revenue.

Technological

No material technology, product, or R&D updates were reported this month.

R&D intensity remains modest at 3.6% of revenue, suggesting limited near-term technology-driven upside absent new product news.

Legal

No new litigation, compliance, or legal proceedings were reported this month.

Interest coverage remains negative at -2.7x, which keeps financial covenant and creditor scrutiny a continuing risk.

Environmental

No new environmental or sustainability developments were reported this month.

Capital intensity is manageable, with capex at 3.7% of revenue, but there was no fresh evidence of environmental initiatives or risks.